&nbsp;

Aug 2025

Drug

trametinib

Other Name(s): Mekinist®

Quick Link(s):

Jun 2025

Regimen

TMZL

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

temozolomide

Drugs Used:

temozolomide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

TRAM

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

Exceptional Access Program

trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria

Drugs Used:

trametinib

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

TOPO(W)

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Drugs Used:

topotecan

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

TMZL

Cancer Type:

Central Nervous System

Intent: Adjuvant

Funding:

ODB - General Benefit

temozolomide

Drugs Used:

temozolomide

Quick Link(s):

Regimen Monograph

Aug 2025

Drug

trifluridine / tipiracil

Other Name(s): Lonsurf®

Quick Link(s):

Nov 2024

Regimen

TMXFRIBO

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

tamoxifen

Drugs Used:

tamoxifen,

ribociclib (Unfunded)

Quick Link(s):

Regimen Monograph

Sep 2025

Drug

tucatinib

Other Name(s): Tukysa™

Quick Link(s):

Feb 2025

Regimen

TEBE; TEBE(RAMP)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma

High Cost Therapy Funding Program

Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma

Drugs Used:

tebentafusp

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

TECL; TECL(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma

High Cost Therapy Funding Program

Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma

Drugs Used:

teclistamab

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

TRIFTIPI+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer

trifluridine / tipiracil,

Drugs Used:

bevacizumab